Evidence map›Paper›PMID 29147221›Full record

ArticleWorld journal of oncology2011

Evaluation of Serum Zinc Level Under Malignant Condition and its Possible Implication on Improving Cell-Mediated Immunity During Cancer Progression.

Prabir K Chakravarty

Open access · hybridAbstract read
In one paragraph

Article in World journal of oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Prabir K ChakravartyTumor Immunity and Gene therapy Unit, Chittaranjan National Cancer Institute, S.P. Mukherjee Road, Calcutta-700025, India.
Chittaranjan National Cancer Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundZinc is an essential trace element required for different biological functions in a living body. Evaluating its concentration and effect during malignancy is important not only to assess the disease activity but also to evaluate its role in some important biological activities like immunity.

methodsThe experiments were carried out in transplanted, chemically induced and spontaneous tumors in mice. The serum zinc concentration (SZC) was determined under malignant condition and following treatment of solid tumor with anti-cancer agents. The importance of evaluating Cu/Zn ratio (CZR) was also determined. To evaluate its role in immune response during malignancy, studies were carried out on induced tumor bearing animals.

resultsThe results showed that SZC had an inverse correlation with the progression of the disease. It was significantly reduced in all forms of malignancy, more so in spontaneous and induced forms of the disease. Extensive studies done with the solid form of induced tumor, established the importance of estimating the concentration of Zn, in addition to that of copper, in assessing the disease activity following treatment with anti-cancer agents. With regression of the tumor mass, there was a significant elevation in the SZC and depression in the serum copper concentration (SCC) compared to their levels prior to treatment. This was also reflected on the value of copper zinc ratio (CZR); with the onset of tumor regression, a significant reduction in CZR was noted in the tumor bearing animals compared to their untreated levels. As the state of 'regression' in the tumor mass was maintained for a considerable period of time following treatment with anti-cancer agents along with elevated zinc levels, we considered the role of zinc in controlling the tumor growth, indirectly. We observed that zinc is able to stimulate lymphocyte proliferation that may directly impact on the immune response of tumor bearing host.

conclusionsZinc appears to play a role in tumor progression and regression and in stimulating lymphocyte proliferation. It is hypothesized that supplementing zinc to malignant subjects prior to and following therapeutic intervention with anti-cancer agents could help improve immune response of the host against existing tumor.

Indexed as

CancerCell-Mediated immunitySerum zinc

Identifiers

PMID29147221
PMCPMC5649884
OpenAlexW2015394158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.